BioSpace News Archive

Medicenna Therapeutics Corp. today announced dosing of the first patient in the Phase 2 monotherapy dose expansion portion of the Phase 1/2 ABILITY (ABeta-only IL-2 ImmunoTherapY) study evaluating MDNA11, a long-acting, beta-only interleukin-2 (IL-2) super-agonist.

Acurx Pharmaceuticals, Inc. announced today that the Company will discuss its third quarter 2023 financial results on Tuesday, November 14, 2023, at 8:00 am ET.

Vision Innovation Partners (“VIP”), a leading Mid-Atlantic eye care platform with nearly 70 locations, today announced the promotion of existing board member and current President, Chris Moore, to Chief Executive Officer, as part of a planned transition in the senior leadership of the company.

A new study uses key Promega technologies to evaluate reported anti-inflammation molecules in the context of live cells.

Vedanta Biosciences today announced that management will host investor meetings at the Wells Fargo Virtual Private Biotech Symposium being held on Wednesday, November 1, 2023.

GSK plc (LSE/NYSE: GSK) today announced positive preliminary results from its phase III trial [NCT05590403] evaluating the immune response and safety of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 50 to 59, including those at increased risk of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) due to certain underlying medical conditions.

Dyno Therapeutics Launches Dyno eCap 1™ Vector, a Field-Leading AAV Capsid for Eye Gene Therapies.

Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its third-quarter financial results on Wednesday, November 8, 2023 after market close and will host a conference call that same day at 4:30pm ET.

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company’s interim report for the period January-September 2023, has been published.

Medivir AB announced the company plans to report new and updated data from its ongoing phase 2a study with the candidate drug fostrox in combination with Lenvima® in advanced hepatocellular carcinoma.